250 filings
Page 7 of 13
8-K
jqj6f1q agcsjth8my
7 Sep 17
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma
12:00am
8-K
gd40iw2i0pu872 5s3
28 Jul 17
NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program
12:00am
8-K
0ekvdss ye
27 Jul 17
NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802
12:00am
8-K
iepqn9g52z9tg3bumc5
17 Jul 17
Departure of Directors or Certain Officers
12:00am
8-K
q24ll
10 Jul 17
NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs
12:00am
8-K
aj9 f218pkc9h
23 Jun 17
Other Events
12:00am
8-K
hxcs mp3t91h
8 Jun 17
Other Events
12:00am
8-K
6lg6y ttge8735o1a3td
5 Jun 17
Other Events
12:00am
8-K
wj50nyz 2gj54k1
2 Jun 17
Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer
12:00am
8-K
0jc0og29ok7vhq74tg7
18 May 17
Other Events
12:00am
8-K
st45kjjf wgqiyz
17 May 17
Data from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017
12:00am
8-K
iin2ni90psdxisaxa4s
17 May 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
zhayg3c403ktd20gf j0
4 May 17
NewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance
12:00am
8-K
hd790onl7v
4 Apr 17
Other Events
12:00am
8-K
qcp4y2
20 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
gumorrqso si0i
1 Mar 17
NewLink Genetics Announces Presentation of Two Abstracts at AACR
12:00am
8-K
kbpwn4 2qx
28 Feb 17
Results of Operations and Financial Condition
12:00am
8-K
n9qgmmz3boqazzatf
5 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K/A
swc ct79k3xqsme5s3
13 Dec 16
Entry into a Material Definitive Agreement
12:00am
8-K
v2t770vrdjye
29 Nov 16
Entry into a Material Definitive Agreement
12:00am